Flex Pharma today said that its lead drug has a big problem that is forcing the little biotech to scrap mid-stage studies and hunker down — slashing 60% of its workforce as it searches for a way out of the dilemma.
The problem, not disclosed until now, is that the cramping drug FLX-787 is not tolerable to a subset of patients at 30 mg. Now they need to go back and do some basic formulation and dosing work to fix the issue — but with a beaten down share price, the company doesn’t have the cash to do it alone.
It has even less room to move today, with its stock cratering 75%, wiping out the bulk of the $75 million market cap it started the day with. The stock is down to about $1, a far cry from the $16 it priced at in 2015, when Christoph Westphal took the company he founded public, touting the involvement of Nobel Prize-winning neuroscientist and athlete Rod MacKinnon.
The company also developed a consumer anti-cramping product called HotShot, another strategy that Westphal has employed in the past, with mixed success. Westphal — best known for selling Sirtris to GSK for $720 million — left the CEO job at Flex a year ago. He also briefly ran GSK’s venture group, SR One, then set up Verastem, which wound up hitting a brick wall of its own before going in a new direction.
Flex will now operate with a skeleton crew while they go out in search of a deal, and they’d be happy to consider a buyout offer.
“In the past few months we have reported positive efficacy data in two serious and distinctly different neurological diseases: multiple sclerosis (MS) and ALS. We believe that these clinical data demonstrate the clear potential of FLX-787 as a symptomatic therapy to reduce painful cramps and spasms in these patient populations,” stated Bill McVicar, who took the helm after Westphal left.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 31,500+ biopharma pros who read Endpoints News by email every day.Free Subscription